00:50:30 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2023-10-26 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-04 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning GENT 0.00 NOK
2022-05-18 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-05 Ordinarie utdelning GENT 0.00 NOK
2021-05-04 Årsstämma 2021
2021-04-16 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-10-29 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning GENT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-21 Extra Bolagsstämma 2019
2019-05-10 Ordinarie utdelning GENT 0.00 NOK
2018-07-13 Extra Bolagsstämma 2018
2018-06-13 Ordinarie utdelning GENT 0.00 NOK
2018-02-27 Bokslutskommuniké 2017
2017-06-06 Årsstämma 2017

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Gentian Diagnostics är ett norskt bolag som utvecklar olika produkter inom hälsovård. Exempel är diagnostiska test med målet att utveckla och effektivisera diagnostisk behandling, vilket innefattar behandling utav cancer och hjärt- och kärlsjukdomar. En stor del av verksamheten innefattar FoU utveckling. Bolaget grundades 1998 och har sitt huvudkontor i Moss.
2022-05-18 12:22:11
The annual general meeting of Gentian Diagnostics ASA was held on 18 May 2022.
All the proposed resolutions on the agenda were approved in accordance with the
notice for the meeting, which were published on 27 April 2022.

The minutes of the annual general meeting are enclosed.

The board of directors now consist of 8 members of which the following were
re-elected:

Tomas Settevik (Chair)
Espen Tidemann Jørgensen
Kari E. Krogstad
Susanne Stuffers
Tomas Kramar

The following persons were elected as new board members:

Monika Neumann
Monika Neuman has 20 years of experience from the diagnostics industry,
currently holding a position as Managing Director for Sarstedt Group in the
Nordics. She has previously had several international and commercial leadership
roles like Head of Sales, EMEA , and VP Global Business Management. During the
past 4 years, Ms Neuman has been working at Siemens Healthineers Laboratory
Diagnostics headquarters in Tarrytown, NY, where she was closely collaborating
with R&D, Manufacturing, Marketing, and Customer Service to set a successful
strategy for launch and implementation of a new product portfolio on the global
IVD market.

Ms Neuman holds a MSc degree in Biochemistry and a PhD degree in Clinical
Bacteriology from Medical Faculty at Göteborg University in Sweden.

Fredrik Thoresen
Fredrik Thoresen is a partner in Andenaesgruppen where he joined in 2021. Prior
to joining Andenaesgruppen, Mr. Thoresen worked as a Portfolio Manager at
Storebrand Asset Management and as an Equity Research Analyst at SEB. Mr.
Thoresen has also previous buy- and sell-side experience from DNB and Sector
Asset Management.

Mr. Thoresen has an MBA in International Business from Middlebury Institute of
International Studies, Monterey, California and a bachelor's degree in Computer
Science and Economics from Augustana University, Sioux Falls, South Dakota.

Frank Frantzen
Frank Frantzen has more than 35 years of experience from the diagnostic
industry. He has served as principal scientist and has directed larger R&D units
in the international IVD companies Axis-Shield, Alere and Abbott. Mr. Frantzen
left his Senior Director R&D position at Abbott in 2021 and is currently serving
as Chief Technology Officer in CardiNor AS.

Mr. Frantzen holds a master's degree in chemistry and a Ph.D. in
chemistry/biotechnology/IVD-technology, both from the Norwegian University of
Science and Technology in Trondheim.

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

IR Contact:
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.com
Cell phone: +47 919 06 525